Opus Genetics Inc (IRD) is now in the Overvalued zone, suggesting that its current forward PS ratio of 10.24 is considered Overvalued compared with the five-year average of -2.15. The fair price of Opus Genetics Inc (IRD) is between 0.86 to 2.74 according to relative valuation method. Compared to the current price of 4.08 USD , Opus Genetics Inc By Overvalued By 48.67%.

Relative Value

Fair Zone

0.86-2.74

Current Price：4.08

48.67%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Opus Genetics Inc (IRD) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Opus Genetics Inc (IRD) has a current Price-to-Book (P/B) ratio of 22.93. Compared to its 3-year average P/B ratio of 7.62, the current P/B ratio is approximately 201.10% higher. Relative to its 5-year average P/B ratio of 7.62, the current P/B ratio is about 201.10% higher. Opus Genetics Inc (IRD) has a Forward Free Cash Flow (FCF) yield of approximately -22.47%. Compared to its 3-year average FCF yield of -35.14%, the current FCF yield is approximately -36.05% lower. Relative to its 5-year average FCF yield of -35.14%, the current FCF yield is about -36.05% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for IRD competitors is 3.32, providing a benchmark for relative valuation. Opus Genetics Inc Corp (IRD.O) exhibits a P/S ratio of 10.24, which is 207.94% above the industry average. Given its robust revenue growth of -20.38%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of IRD increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of IRD in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is IRD currently overvalued or undervalued?

What is Opus Genetics Inc (IRD) fair value?

IRD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Opus Genetics Inc (IRD) is between 0.86 to 2.74 according to relative valuation method.

How does IRD's valuation metrics compare to the industry average?

The average P/S ratio for IRD's competitors is 3.32, providing a benchmark for relative valuation. Opus Genetics Inc Corp (IRD) exhibits a P/S ratio of 10.24, which is 207.94% above the industry average. Given its robust revenue growth of -20.38%, this premium appears unsustainable.

What is the current P/B ratio for Opus Genetics Inc (IRD) as of Mar 02 2026?

As of Mar 02 2026, Opus Genetics Inc (IRD) has a P/B ratio of 22.93. This indicates that the market values IRD at 22.93 times its book value.

What is the current FCF Yield for Opus Genetics Inc (IRD) as of Mar 02 2026?

As of Mar 02 2026, Opus Genetics Inc (IRD) has a FCF Yield of -22.47%. This means that for every dollar of Opus Genetics Inc's market capitalization, the company generates -22.47 cents in free cash flow.

What is the current Forward P/E ratio for Opus Genetics Inc (IRD) as of Mar 02 2026?

As of Mar 02 2026, Opus Genetics Inc (IRD) has a Forward P/E ratio of -4.73. This means the market is willing to pay $-4.73 for every dollar of Opus Genetics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Opus Genetics Inc (IRD) as of Mar 02 2026?

As of Mar 02 2026, Opus Genetics Inc (IRD) has a Forward P/S ratio of 10.24. This means the market is valuing IRD at $10.24 for every dollar of expected revenue over the next 12 months.

IRD Valuation